Peripheral blood MRD correlates with treatment benefit in CLL

Print Friendly, PDF & Email


Poster session at ASCO 2018
Photo by © ASCO/Scott Morgan 2018
Minimal residual disease (MRD) kinetics confirms the high, durable MRD-negativity with venetoclax plus rituximab in relapsed/refractory chronic lymphocytic leukemia (CLL), according to a further examination of the phase 3 MURANO study. The new results show higher concordance in MRD-negativity between bone marrow and peripheral... [Read Article]
Print Friendly, PDF & Email

‘Excellent’ survival with HCT despite early treatment failure in FL

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
Autologous and allogeneic hematopoietic stem cell transplantation (HCT) both offer excellent long-term survival in follicular lymphoma (FL) patients who experience early treatment failure, an analysis of a large transplant registry suggests. Five-year survival rates exceeded 70% for patients who received autologous or matched sibling donor (MSD) transplants, according to... [Read Article]
Print Friendly, PDF & Email

Ibrutinib and venetoclax combo promising in front-line CLL

Print Friendly, PDF & Email


Attendees at ASCO 2018 Annual Meeting
Photo by © ASCO/Zach Boyden-Holmes 2018
Ibrutinib combined with venetoclax is showing promising clinical activity in the front-line treatment of patients with chronic lymphocytic leukemia (CLL), according to investigators for the CAPTIVATE study. In the first 30 patients, 77% of treatment-naïve patients had undetected minimal residual disease (MRD) in... [Read Article]
Print Friendly, PDF & Email

Chemo-free combo provides potential first-line option for FL

Print Friendly, PDF & Email


Attendee at ASCO 2018
Photo by © ASCO/Scott Morgan 2018
A chemotherapy-free combination of lenalidomide plus rituximab shows similar efficacy and a different safety profile to chemotherapy plus rituximab (R-chemo) followed by rituximab maintenance in patients with previously untreated follicular lymphoma (FL). According to investigators, the multicenter, international phase 3 RELEVANCE trial is the first... [Read Article]
Print Friendly, PDF & Email

Polatuzumab plus BR improves efficacy in DLBCL

Print Friendly, PDF & Email


Attendees at ASCO 2018 Annual Meeting
Photo by © ASCO/Zach Boyden-Holmes 2018
Polatuzumab vedotin, when added to bendamustine (B) and rituximab (R), significantly improved response and survival rates in a cohort of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to randomized phase 2 study results. By contrast, there were no such improvements in... [Read Article]
Print Friendly, PDF & Email

Single-agent acalabrutinib ‘impressive’ in patients with WM

Print Friendly, PDF & Email


McCormick Place during 2018 ASCO Annual Meeting
Photo by © ASCO/Rodney White 2018
Acalabrutinib monotherapy was highly effective in Waldenström’s macroglobulinemia (WM) in a phase 2 study, investigator Roger Owen, MD, reported at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO). The BTK inhibitor was effective in both treatment naïve and... [Read Article]
Print Friendly, PDF & Email

Older, cheaper drug formulation to remain available

Print Friendly, PDF & Email


Imbruvica (ibrutinib)
Photo courtesy of Janssen
The 140 mg capsules of Imbruvica® (ibrutinib) will remain on the market, according to Pharmacyclics LLC. Pharmacyclics (an AbbVie company) and Janssen had planned to discontinue the capsules after introducing a single-tablet formulation of Imbruvica earlier this year. However, the companies received negative feedback about the discontinuation... [Read Article]
Print Friendly, PDF & Email

Regimen can improve DFS in newly diagnosed T-ALL

Print Friendly, PDF & Email


Vials of drugs
Photo by Bill Branson
The addition of nelarabine can improve treatment outcomes for certain patients with T-cell acute lymphoblastic leukemia (T-ALL), according to a phase 3 trial. Patients with newly diagnosed, intermediate- or high-risk T-ALL had a significant improvement in 4-year disease-free survival (DFS) if they received nelarabine in addition to chemotherapy... [Read Article]
Print Friendly, PDF & Email

Umbralisib has ‘distinct’ safety profile

Print Friendly, PDF & Email


Micrograph showing CLL
Phase 1 trial results suggest umbralisib, a PI3Kδ/CK1ε inhibitor, can be safe and active in patients with relapsed or refractory B-cell malignancies. Researchers said the safety profile of umbralisib “was distinct from that of other PI3Kδ inhibitors,” as it produced few immune-mediated adverse events (AEs). Umbralisib also produced an objective response... [Read Article]
Print Friendly, PDF & Email